DNTH (Dianthus Therapeutics) Research & Development: $153.16 Mil (TTM As of Mar. 2026)


DNTH Dianthus Therapeutics Inc DNTH
22 GF Score
Price $94.34
GF Value $2.91
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Dianthus Therapeutics Research & Development?

Dianthus Therapeutics DNTH +4.58% 22 Research & Development is $153.16 Mil as of Mar. 2026. GuruFocus rates DNTH with a GF Score™ of 22/100 and a GF Value™ of $2.91 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Dianthus Therapeutics's Research & Development for the three months ended in Mar. 2026 was $34.53 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $153.16 Mil.

Dianthus Therapeutics  (NAS:DNTH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Dianthus Therapeutics Research & Development Related Terms

Dianthus Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Dianthus Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dianthus Therapeutics Research & Development Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
12.61 29.38 32.84 83.11 145.64

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.00 26.25 32.49 59.90 34.53
DNTH
22GF Score
Dianthus Therapeutics Inc DNTH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dianthus Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $153.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $153.16 Mil mean?
Dianthus Therapeutics (DNTH) has a Research & Development of $153.16 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Dianthus Therapeutics and its competitors.
Is Dianthus Therapeutics' Research & Development too high?
Dianthus Therapeutics' current Research & Development is $153.16 Mil. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' Research & Development compare to CAI and TNGX?
Dianthus Therapeutics' Research & Development of $153.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Dianthus Therapeutics and its competitors. Dianthus Therapeutics's current Research & Development is $153.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (DNTH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.91, compared to a current price of $94.34 — trading 3141.9% above its estimated fair value. The current Research & Development is $153.16 Mil. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Dianthus Therapeutics (DNTH), the current Research & Development is $153.16 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dianthus Therapeutics (DNTH) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of $94.34 is trading 3141.9% above its estimated GF Value™ of $2.91. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for DNTH:

  • Research & Development: $153.16 Mil
  • GF Value™: $2.91 vs. price of $94.34 (3141.9% above fair value)
  • GF Score™: 22/100 with 7 warning signs

No single metric tells the full story. See the DNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dianthus Therapeutics Business Description

Other Exchanges 87E:Germany
Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score

Get the complete analysis for DNTH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$94.34
Price
$2.91
GF Value